Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Shield Therapeutics plc logo — Helping patients become people again

Shield Therapeutics plc

Helping patients become people again

Founded 2008 United Kingdom United Kingdom 71 employees Post-IPO Debt Total: $33.20M Biotechnology, Health and Wellness +1

General Information

Company Name Shield Therapeutics plc
Founded Year 2008
Location United Kingdom United Kingdom
Founders / Decision Makers
Team member
Employees 71
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Shield Therapeutics plc. To contact Shield Therapeutics plc, visit shieldtherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Shield Therapeutics plc compare?

A PDF of Shield Therapeutics plc and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Shield Therapeutics plc soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Shield Therapeutics plc

Shield Therapeutics plc is a UK-based specialty pharmaceutical company that focuses on addressing iron deficiency through its lead product, Accrufer®/Feraccru® (ferric maltol). The company has already launched Accrufer® in the US, while Feraccru® is commercialized in the UK and European Union by Norgine B.V. Shield also holds exclusive license agreements with companies in China, Hong Kong, Macau, Taiwan, Republic of Korea, and Canada for the development and commercialization of Accrufer®/Feraccru®. Founded in 2008, Shield Therapeutics plc recently secured a significant £5.00MPost-IPO Equity investment on 28 September 2023 from investors including Cavendish Corporate Finance, Peel Hunt, and AOP Global Health. With a slogan of "Helping patients become people again," Shield Therapeutics plc's innovative approach in the biotechnology and pharmaceutical industries has garnered significant attention and investment, positioning it as an influential player in the market.

Business keywords: specialty pharmaceuticals, iron deficiency, Accrufer, Feraccru, global pivotal Phase III studies, inflammatory bowel disease, chronic kidney disease, Switzerland, independent pharmaceutical company, global commercialization, mineral-derived hospital pharmaceuticals, Norgine B.V., Beijing Aosaikang Pharmaceutical Co., Ltd., Korea Pharma Co., Ltd., KY Pharmaceuticals Inc.

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $20.00M 1
SWK Holdings
28 Sep 2023
Post IPO Equity £5.00M 3
Cavendish Corporate Finance, Peel Hunt +1
28 Sep 2023
Series A €8.20M 1
Inventages
Inventages
01 Jun 2011

Shield Therapeutics plc Alternatives & Competitors

Shield Therapeutics plc vs
VISEN Pharmaceuticals
VISEN Pharmaceuticals China

Achieve better treatment processes and outcomes by combining global expertise and strength in endocr...

Series B
42 employees
Biotechnology, Life Sciences
Compare Shield Therapeutics plc vs VISEN Pharmaceuticals

FAQ About Shield Therapeutics plc

Helping patients become people again
Shield Therapeutics plc was founded in 2008.
Shield Therapeutics plc is headquartered in United Kingdom.
Shield Therapeutics plc operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on specialty pharmaceuticals, iron deficiency, Accrufer and Feraccru.
Shield Therapeutics plc has approximately 71 employees.
Shield Therapeutics plc has completed 3 funding rounds, raising a total of $33.20M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Shield Therapeutics plc include VISEN Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Shield Therapeutics plc and VISEN Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Shield Therapeutics plc, https://bouncewatch.com/company/shield-therapeutics-plc, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout